Bright Minds Biosciences Inc. (DRUG)Healthcare | Biotechnology | New York, United States | NasdaqCM
89.90 USD
+1.25
(1.410%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 90.65 +0.75 (0.834%) ⇧ (April 17, 2026, 5:50 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 1:19 p.m. EDT
Bright Minds Biosciences (DRUG) shows strong short-term momentum with a recent price surge and positive analyst sentiment, suggesting a slight upside lean. However, its long-term fundamentals are weak due to negative earnings and poor financial health, warranting caution. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.078948 |
| AutoETS | 0.078952 |
| MSTL | 0.100037 |
| AutoTheta | 0.224842 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 3.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.299 |
| Excess Kurtosis | -1.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.117 |
| Market Cap | 879,865,792 |
| Forward P/E | -11.59 |
| Beta | -0.11 |
| Website | https://brightmindsbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8190656 |
| Address1 | 19 Vestry Street |
| All Time High | 123.75 |
| All Time Low | 0.93 |
| Ask | 90.1 |
| Ask Size | 1 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 164,620 |
| Average Daily Volume3 Month | 136,917 |
| Average Volume | 136,917 |
| Average Volume10Days | 164,620 |
| Beta | -0.113 |
| Bid | 89.76 |
| Bid Size | 1 |
| Book Value | 8.348813 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 89.9 |
| Current Ratio | 57.368 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 92.39 |
| Day Low | 89.465 |
| Debt To Equity | 0.117 |
| Display Name | Bright Minds Biosciences |
| Earnings Timestamp End | 1,778,875,200 |
| Earnings Timestamp Start | 1,778,875,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 790,922,816 |
| Eps Current Year | -6.832 |
| Eps Forward | -7.759418 |
| Eps Trailing Twelve Months | -2.01 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 78.7052 |
| Fifty Day Average Change | 11.194801 |
| Fifty Day Average Change Percent | 0.14223713 |
| Fifty Two Week Change Percent | 181.90656 |
| Fifty Two Week High | 123.75 |
| Fifty Two Week High Change | -33.85 |
| Fifty Two Week High Change Percent | -0.27353534 |
| Fifty Two Week Low | 23.175 |
| Fifty Two Week Low Change | 66.725006 |
| Fifty Two Week Low Change Percent | 2.8791804 |
| Fifty Two Week Range | 23.175 - 123.75 |
| Financial Currency | CAD |
| First Trade Date Milliseconds | 1,616,419,800,000 |
| Float Shares | 6,612,402 |
| Forward Eps | -7.759418 |
| Forward P E | -11.58592 |
| Free Cashflow | -7,701,105 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 26 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1158 |
| Held Percent Institutions | 0.67565 |
| Implied Shares Outstanding | 9,787,161 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-11-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,689,292,800 |
| Last Split Factor | 1:5 |
| Long Business Summary | Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York. |
| Long Name | Bright Minds Biosciences Inc. |
| Market | us_market |
| Market Cap | 879,865,792 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_691048918 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -19,844,276 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 880,185,882 |
| Number Of Analyst Opinions | 3 |
| Open | 90.34 |
| Operating Cashflow | -13,013,126 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 647 865 8622 |
| Post Market Change | 0.75 |
| Post Market Change Percent | 0.8342603 |
| Post Market Price | 90.65 |
| Post Market Time | 1,776,462,659 |
| Previous Close | 88.65 |
| Price Eps Current Year | -13.158666 |
| Price Hint | 2 |
| Price To Book | 10.767998 |
| Profit Margins | 0.0 |
| Quick Ratio | 56.586 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | 1.25 |
| Regular Market Change Percent | 1.41004 |
| Regular Market Day High | 92.39 |
| Regular Market Day Low | 89.465 |
| Regular Market Day Range | 89.465 - 92.39 |
| Regular Market Open | 90.34 |
| Regular Market Previous Close | 88.65 |
| Regular Market Price | 89.9 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 114,683 |
| Return On Assets | -0.15718001 |
| Return On Equity | -0.26979 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 9,787,161 |
| Shares Percent Shares Out | 0.0719 |
| Shares Short | 703,646 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 488,136 |
| Short Name | Bright Minds Biosciences Inc. |
| Short Percent Of Float | 0.0934 |
| Short Ratio | 4.84 |
| Source Interval | 15 |
| State | NY |
| Symbol | DRUG |
| Target High Price | 193.13445 |
| Target Low Price | 144.8711 |
| Target Mean Price | 161.47545 |
| Target Median Price | 146.42079 |
| Total Cash | 89,047,864 |
| Total Cash Per Share | 9.098 |
| Total Debt | 104,900 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.01 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 63.173023 |
| Two Hundred Day Average Change | 26.726978 |
| Two Hundred Day Average Change Percent | 0.42307582 |
| Type Disp | Equity |
| Volume | 114,683 |
| Website | https://brightmindsbio.com |
| Zip | 10,013 |